DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE

Pre-Launch

dextromethorphan hydrobromide; quinidine sulfate

ANDAORALCAPSULE

Lifecycle

Pre-Launch

Data completeness

2/8 — Basic

DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE (dextromethorphan hydrobromide; quinidine sulfate) by R-Pharm US is (dm) is a sigma-1 receptor agonist and an uncompetitive nmda receptor antagonist. Approved for pseudobulbar affect (pba).

Drug data last refreshed 1mo ago

Mechanism of Action

(DM) is a sigma-1 receptor agonist and an uncompetitive NMDA receptor antagonist. Quinidine increases plasma levels of dextromethorphan by competitively inhibiting cytochrome P450 2D6, which catalyzes a major biotransformation pathway for dextromethorphan. The mechanism by which dextromethorphan…

Indications (1)

pseudobulbar affect (PBA)

Company

Worked on DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.